April 19th 2024
Druggable gene aberrations and predictive biomarkers has allowed for the use of next-generation sequencing technologies to grow.
February 14th 2024
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Veliparib Demonstrates Clinical Activity in Patients with BRCA-Positive Breast, Ovarian Tumors
September 6th 2014The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.
Read More
New Insights From ENCODE Datasets, NIH Issues Finalized Genomic Data Sharing Policy
September 2nd 2014A series of papers have been published in the journal Nature in which researchers conducted detailed comparisons of the worm, fly, and human genomes using data from the ENCODE and modENCODE projects.
Read More
Challenges in the Field of Hereditary Breast Cancer
August 8th 2014Claudine Isaacs, MD, professor, medical Director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses some of the challenges physicians are facing in the field of hereditary breast cancer.
Watch
A New Concept to Broaden Access to Molecular Testing
August 6th 2014During a 2013 discussion on treating NSCLC, a group of oncologists were asked what share of cancer patients have access to molecular testing. The answers varied: One said he guessed 40% to 50%, another said "a large minority."
Read More
Validating Gene Signatures in mCRPC
May 6th 2014William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the process of validating a whole-blood prognostic signature in metastatic castration-resistant prostate cancer (mCRPC).
Watch
Combining and Sequencing Agents with Immunotherapies in Prostate Cancer
April 23rd 2014Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.
Watch
The Outlook for BRCA Genetic Testing and Counseling
April 2nd 2014The US Supreme Court’s landmark decision last June, mandating that an individual’s genes cannot be patented, transformed the genetic testing landscape and opened the marketplace to a host of new and complicated testing options.
Read More
Findings From Next-Generation Sequencing Offer Promise for New Breast Cancer Therapies
March 24th 2014The most promising novel therapeutics in development for patients with breast cancer focus primarily on targeting activating mutations in combinations that are based on findings from next-generation sequencing.
Read More
AR Findings Highlight Detailed Tumor-Profiling Study
March 7th 2014A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression.
Read More